DEVELOPMENT CONCEPT - NOT FOR SALE

LONGEVITY CELLULAR+

Premium public development concept for a once-daily 10 g high-barrier sachet.

Prepared by	Stasinos Sikalias, Pharmacist | CEO & R&D Manager
Audience	Potential development, distribution and commercial partners
Document date	07 September 2026
Version	1.0

Educational and business-development publication. It does not replace product-specific development, risk assessment, current official guidance, regulatory review, validated methods, stability data or professional clinical judgement.

ΕΛΛΗΝΙΚΗ ΕΚΔΟΣΗ

Concept status

Αναπτυξιακή πρόταση - δεν αποτελεί τελικό εμπορικό προϊόν, εγκεκριμένη ετικέτα ή προσφορά προς πώληση. Ιδιαίτερα για nicotinamide riboside, CoQ10 grade και vitamin premixes απαιτείται επιβεβαίωση του ακριβούς commercial material, legal basis, compositional limits και label wording για την αγορά στόχο.

Working composition per sachet

H current architecture περιλαμβάνει creatine monohydrate 3.000 mg, glycine 2.500 mg, TMG 1.500 mg, magnesium με στόχο 120 mg, nicotinamide riboside chloride 300 mg, microencapsulated CoQ10 preparation 250 mg με στόχο παροχής 100 mg CoQ10, vitamin C 100 mg και vitamin D/B-vitamin premixes προς οριστικοποίηση.

Διαφοροποίηση

Το concept προσθέτει premium cellular-energy layer πάνω σε foundation creatine/glycine/TMG. Η διαφοροποίηση πρέπει να εκφραστεί ως formulation transparency, dose disclosure, packaging discipline και quality documentation - όχι ως υπόσχεση μεταβολής βιολογικής ηλικίας ή πρόληψης νόσου.

Product format

Μία ημερήσια μονοδόση σε 10 g high-barrier sachet, 30 sachets ανά συσκευασία. Η oxidative και moisture sensitivity των επιμέρους συστατικών καθιστά κρίσιμα το qualified material form, το barrier pack, το headspace/oxygen strategy και τις stability-indicating tests.

Development gates

EU regulatory confirmation για το exact NR grade/use, qualification microencapsulated CoQ10, taste masking, blend and fill feasibility, moisture/oxygen risk control, analytical methods, pilot, stability, packaging and final legal/claims review.

ENGLISH VERSION

Concept status

Development concept - not a final commercial product, approved label or offer for sale. Nicotinamide riboside, the CoQ10 grade and vitamin premixes require confirmation of the exact commercial material, legal basis, compositional limits and label wording for the target market.

Working composition per sachet

The current architecture includes creatine monohydrate 3,000 mg, glycine 2,500 mg, TMG 1,500 mg, magnesium targeting 120 mg, nicotinamide riboside chloride 300 mg, a 250 mg microencapsulated CoQ10 preparation targeting 100 mg CoQ10, vitamin C 100 mg, and vitamin D/B-vitamin premixes to be finalised.

Differentiation

The concept adds a premium cellular-energy layer to a creatine/glycine/TMG foundation. Differentiation should be expressed through formulation transparency, full dose disclosure, packaging discipline and quality documentation - not through promises to change biological age or prevent disease.

Product format

One daily 10 g high-barrier sachet, 30 sachets per pack. The oxidative and moisture sensitivity of components make qualified material form, barrier packaging, headspace/oxygen strategy and stability-indicating tests critical.

Development gates

EU regulatory confirmation for the exact NR grade/use, qualification of microencapsulated CoQ10, taste masking, blend/fill feasibility, moisture/oxygen risk control, analytical methods, pilot, stability, packaging and final legal/claims review.

Selected references and standards

ICH Q8(R2), Pharmaceutical Development, International Council for Harmonisation.

ICH Q9(R1), Quality Risk Management, International Council for Harmonisation.

ICH Q10, Pharmaceutical Quality System, International Council for Harmonisation.

European Commission, EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice.

EU GMP Annex 15, Qualification and Validation.

FIP/WHO, Joint Guidelines on Good Pharmacy Practice: Standards for Quality of Pharmacy Services.